Skip to content

Clinical Efficacy of Different Revision Times in the Reulceration Rate in Persons with Diabetes and Remission

Clinical Efficacy of Different Revision Times in the Reulceration Rate in Persons with Diabetes and Remission: a Three Arm Double Blind Randomized Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06143215
Acronym
Diatime
Enrollment
148
Registered
2023-11-22
Start date
2024-01-10
Completion date
2025-02-15
Last updated
2025-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot

Keywords

Diabetic foot, Reulceration, Prevention

Brief summary

The goal of this three arms randomized clinical trial is to compare different revision times in persons with diabetes at high risk of suffering a diabetic foot reulceration (patients in remission). The literature suggests to clinically check the patients in a 4-12 weeks basis, despite this, this recommendation is based in expert opinions. The main question it aims to answer is: \- Does different revision times could affect the reulceration rate in persons with diabetes in remission. Different revision time will be 2 weeks, 4 weeks and 6 weeks.

Detailed description

The planned RCT try to elucidate if there exist any difference in ulcer recurrence between different revisions times in persons with a previous healed diabetic foot ulcer and currently under remission. There will exist three different groups for analyses after randomization: * Group 1: patients revised every fourweeks. * Group 2: patients revised every eightweeks. * Group 3: patients revised every twelveweeks. Main outcome measure will include: \- Recurrence: the outcome measure was based on recurrent events in the foot in a binary basis (patient with a recurrent event or patient without a recurrent event), as defined according to the IWGDF guidelines. Recurrent events were considered as breaks in the foot skin at the epidermis and part of the dermis level. Secondary outcome measure will include: * Minor lesions: defined as non ulcerative lesions of the skin on the plantar aspect of the foot and included abundant callus, hemorrhage, or a blister. * Minor amputations: evaluated in a monthly basis during the 1-year prospective period Follow-up period: all the sample will be followed-up depending on the randomization group up to a 1-year prospective period. In every visit de principal investigator will perform debridement of high-risk points, such as minor lesions or calluses.

Interventions

BEHAVIORAL4 weeks revision

In the literature is described to clinically revise patients in a 4-6 weeks basis, despite this expert recommendation, no previous research has clinically evaluated if 4-8-12 weeks revision times could change diabetic foot reulceration rate.

Sponsors

Universidad Complutense de Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Masking description

No masking is possible to be performed in the planned RCT due to the nature of the intervention (time dependent).

Intervention model description

Three arms parallel randomized clinical trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 years or older. * Type 1 or type 2 diabetes. * Presence of diabetic polyneuropathy (diagnosed as an inability to sense the pressure of a 10-g Semmes-Weinstein monofilament at three plantar foot sites and/or a vibration perception threshold \>25 V, as assessed using a bio-tensiometer. * Patients classified as high-risk patients (risk 3 patients according to the IWGDF guidance). Previous healed diabetic foot ulcer.

Exclusion criteria

* Active diabetic foot ulcers during inclusion. * Active Charcot foot process. * Conditions other than diabetes also associated with foot ulcers were excluded from the study as well.

Design outcomes

Primary

MeasureTime frameDescription
Recurrence rateFrom randomization to first documented diabetic foot ulcer appearance, assessed up to 48 weeks.Defined as as break in the foot skin at the epidermis and part of the dermis level.

Secondary

MeasureTime frameDescription
Minor lesion rateFrom randomization to first documented diabetic foot ulcer appearance, assessed up to 48 weeks.Defined as non ulcerative lesions of the skin on the plantar aspect of the foot and included abundant callus, hemorrhage, or a blister.
Minor amputation rateFrom randomization to first documented diabetic foot ulcer appearance, assessed up to 48 weeks.Need for minor amputation secondary to ulcer recurrence

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026